Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBOVAC-Salone: Ad26.ZEBOV and MVA-BN-Filo for Ebola
NCT02509494Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Jun 2019
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zabdeno and Mvabea in Ebola virus disease (EVD) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Solicited Local Adverse Events at Day 738, Number of Participants With Solicited Systemic Adverse Events at Day 738 and 4 more. Started Sep 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02509494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509494.